On August 29, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update of the Company’s business, and host investor meetings, at the 2018 Wells Fargo Healthcare Conference (Press release, Supernus, AUG 29, 2018, View Source [SID1234529356]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, September 5, 2018

Time: 11:25 a.m. ET
Place: The Westin Copley Place, Boston, Mass.

Investors interested in arranging a meeting with the Company’s management during this conference should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company’s website.

On August 29, 2018 Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, reported that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at upcoming conferences (Press release, Aptose Biosciences, AUG 29, 2018, View Source [SID1234529350]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

B. Riley FBR Annual Healthcare Conference
Date: Tuesday, September 4, 2018
Location: New York Marriott East Side

Dr. Rice will be participating on two panels:
9:50 a.m. EDT – A Beginner’s Guide to Blood Cancers
3:25 p.m. EDT – Immuno-oncology Has Made TKIs Obsolete

H.C. Wainwright & Co. 20th Annual Global Investment Conference
Date: Wednesday, September 5, 2018
Time: 8:45 a.m. EDT
Location: The St. Regis New York
Live webcast: Webcast Link
2018 Healthcare Capital and Connections Summit
Date: September 12-13, 2018
Location: Andaz Xintiandi, Shanghai, People’s Republic of China

On August 29, 2018 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported reported that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 2:10 p.m. ET in New York (Press release, Bio-Path Holdings, AUG 29, 2018, View Source [SID1234529311]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed under "Presentations and Publications" in the Media section of the Company’s website at www.biopathholdings.com.

On August 29, 2018 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, reported that it will present at upcoming conferences (Press release, Mannkind, AUG 29, 2018, View Source [SID1234529306]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 am (ET) at the St. Regis Hotel in New York City

Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 1:40 pm (ET) at the Intercontinental New York Barclay Hotel in New York City
Presenting from the Company will be its Chief Executive Officer, Michael Castagna.

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company’s website at View Source

On August 29, 2018 ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, reported it has issued a narrated overview of second quarter 2018 operational results (Press release, ProMIS Neurosciences, AUG 29, 2018, View Source [SID1234529252]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continued to make significant progress on three main priorities in the second quarter of 2018", stated ProMIS Executive Chairman, Eugene Williams. "First, to maintain PMN310 on track for clinical trial start in the second half of 2019 with initiation of cell line development supporting product manufacturing; second, to differentiate the oligomer selectivity of PMN310 as best in class profile for the treatment of Alzheimer’s disease (AD) versus other, less selective amyloid-beta (Aβ) directed therapies in development; and third, to expand our portfolio by developing therapeutic antibodies targeting toxic oligomers of alpha-synuclein for Parkinson’s disease (PD) and toxic aggregates of Tar-DNA binding protein (TDP43) for ALS, with a view to partnering these assets."